Biogaia AB
STO:BIOG B

Watchlist Manager
Biogaia AB Logo
Biogaia AB
STO:BIOG B
Watchlist
Price: 110.2 SEK -0.54% Market Closed
Market Cap: kr10.9B

Relative Value

The Relative Value of one BIOG B stock under the Base Case scenario is 101.95 SEK. Compared to the current market price of 110.2 SEK, Biogaia AB is Overvalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BIOG B Relative Value
Base Case
101.95 SEK
Overvaluation 7%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

BIOG B Competitors Multiples
Biogaia AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Biogaia AB
STO:BIOG B
11.2B SEK 7.6 35.3 28.2 26.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 746 422.5 -160 391.7 -165 649.1 -163 758.9
US
Abbvie Inc
NYSE:ABBV
395.2B USD 6.6 168.3 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
184.2B USD 5.1 26.3 18.8 18.8
US
Gilead Sciences Inc
NASDAQ:GILD
175.6B USD 6 21.7 14.7 14.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD 10.2 32.5 23.9 24.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 087.6 -532.7 -682 -663.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.9B USD 5.5 17 16.2 18.3
AU
CSL Ltd
ASX:CSL
87.8B AUD 3.9 20 9.2 11.4
NL
argenx SE
XBRU:ARGX
43.3B EUR 14 33 66.8 68.6
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.7 -78.2 -70.5
P/S Multiple
Revenue Growth P/S to Growth
SE
Biogaia AB
STO:BIOG B
Average P/S: 3 068 053.6
7.6
10%
0.8
FR
Pharnext SCA
OTC:PNEXF
33 746 422.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
6
4%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 087.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.9
5%
0.8
NL
argenx SE
XBRU:ARGX
14
49%
0.3
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
SE
Biogaia AB
STO:BIOG B
Average P/E: 44.3
35.3
12%
2.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 391.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.3
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
21.7
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
10%
1.7
AU
CSL Ltd
ASX:CSL
20
11%
1.8
NL
argenx SE
XBRU:ARGX
33
42%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Biogaia AB
STO:BIOG B
Average EV/EBITDA: 24.3
28.2
15%
1.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 649.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.8
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.7
7%
2.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -682 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
9.2
8%
1.1
NL
argenx SE
XBRU:ARGX
66.8
810%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -78.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Biogaia AB
STO:BIOG B
Average EV/EBIT: 25.8
26.4
15%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 758.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.8
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.7
13%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.9
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -663.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
13%
1.4
AU
CSL Ltd
ASX:CSL
11.4
11%
1
NL
argenx SE
XBRU:ARGX
68.6
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -70.5 N/A N/A